Results 41 to 50 of about 49,899 (288)

Differential expression of CD163 on monocyte subsets in healthy and HIV-1 infected individuals. [PDF]

open access: yesPLoS ONE, 2011
CD163, a haptoglobin-hemoglobin (Hp-Hb) scavenger receptor, expressed by monocytes and macrophages, is important in resolution of inflammation. Age-related non-AIDS co-morbidities in HIV-infected individuals, particularly dementia and cardiovascular ...
Emma Tippett   +7 more
doaj   +1 more source

Soluble CD163 Levels and CD163+CD14+ Monocyte/Macrophage Counts in Patients with Asthma.

open access: yesIranian journal of immunology : IJI, 2018
CD163-expressing macrophages are involved in the inflammatory response in asthma.To assess sputum and serum soluble CD163 (sCD163) and cytokine levels in patients with asthma. Further discussed was the difference between sCD163 and other classic inflammatory mediators.Sputum was successfully induced in asthma patients (n=85) and healthy controls (n=21).
Zhi, Yue   +6 more
openaire   +3 more sources

RNA‐seq and ATAC‐seq analysis of CD163+ macrophage‐induced progestin‐insensitive endometrial cancer cells

open access: yesCancer Medicine, 2023
Background Progestins are used as fertility‐sparing regimens for young patients with stage 1A endometrioid endometrial cancer (EEC) and atypical endometrial hyperplasia (AEH).
Lulu Wang   +6 more
doaj   +1 more source

CD163: a potential biomarker for lupus nephritis activity. [PDF]

open access: yesLupus Sci Med
Objectives CD163 is a macrophage-associated scavenger receptor shed during inflammatory activation, resulting in measurable soluble CD163 in serum (s) and urine (u). Elevated levels have been reported in inflammatory and immune-mediated conditions, including lupus nephritis (LN).
Gürel E   +11 more
europepmc   +4 more sources

Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases [PDF]

open access: yesInternational Journal of Molecular Sciences, 2020
The macrophage is a key cell in the pro- and anti-inflammatory response including that of the inflammatory microenvironment of malignant tumors. Much current drug development in chronic inflammatory diseases and cancer therefore focuses on the macrophage as a target for immunotherapy.
Skytthe, Maria K.   +2 more
openaire   +4 more sources

Prognostic Implications of Tumor-Associated Macrophages in Oral Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis

open access: yesJournal of Orofacial Sciences
Introduction: Tumor-associated macrophages (TAMs) are the major cellular component in the tumor microenvironment of oral squamous cell carcinoma (OSCC). Several studies have been put forward to assess the role of TAMs in the prognostication of OSCC.
Surya Surendran L   +5 more
doaj   +1 more source

Tissue Levels of CD80, CD163 and CD206 and Their Ratios in Periodontal and Peri-Implant Health and Disease

open access: yesCurrent Issues in Molecular Biology, 2022
This study aimed to compare tissue levels of CD80 (pro-inflammatory macrophage-related surface marker), CD163, and CD206 (anti-inflammatory macrophage-related surface markers), and their ratios in periodontal and peri-implant health and disease ...
Mustafa Yilmaz   +4 more
doaj   +1 more source

The impact of prolonged blockade of the releasing hormone on alterations in cardiac macrophage polarisation subsequent to quercetin administration in rats

open access: yesMìžnarodnij Endokrinologìčnij Žurnal
Background. Cardiomyocytes represent the contractile units of the myocardium, while the maintenance and renewal of the extracellular matrix is a function of fibroblasts.
T.A. Voroshylova   +8 more
doaj   +1 more source

Alterations of Scavenger Receptor CD163 in Diabetes Complications [PDF]

open access: yes, 2023
The progressive and unresolving nature of diabetes complications cause irreversible tissue damage. Inflammation is implicated in diabetes complications at tissue and systemic level.
Siwan, Elisha
core  

CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial

open access: yesOncoImmunology, 2017
The French phase 3 trial (OS 2006) testing zoledronic acid, an osteoclast inhibitor, with chemotherapy and surgery did not improve the outcome of patients with osteosarcoma (OS).
Anne Gomez-Brouchet   +19 more
doaj   +1 more source

Home - About - Disclaimer - Privacy